핵산 치료제 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The global nucleic acid therapeutics market size is expected to reach USD 37.81 Billion in 2034 from USD 10.61 Billion in 2025, growing at a CAGR of 15.17 during 2026-2034.This market is expanding rapidly as advances in molecular biology and genetics enable the development of targeted therapies for complex diseases. Nucleic acid therapeutics, including RNA-based drugs, antisense oligonucleotides, and gene-editing technologies, are transforming treatment approaches for conditions such as cancer, genetic disorders, and infectious diseases. The increasing understanding of genetic mechanisms and the rising demand for personalized medicine are significantly driving market growth. Additionally, the success of mRNA-based vaccines has accelerated interest and investment in nucleic acid technologies across the pharmaceutical industry.

Key growth drivers include advancements in biotechnology and the growing prevalence of chronic and genetic diseases. Pharmaceutical companies and research institutions are investing heavily in the development of innovative therapies that offer higher specificity and effectiveness. The expansion of clinical trials and regulatory approvals for nucleic acid-based drugs is further supporting market growth. Additionally, improvements in delivery systems, such as lipid nanoparticles and viral vectors, are enhancing the stability and efficacy of these therapies.

Future prospects for this market remain highly promising, with continued innovation expected to unlock new therapeutic possibilities. The development of next-generation gene-editing tools and RNA therapies will expand treatment options for previously untreatable conditions. Emerging markets are anticipated to witness increased adoption due to improving healthcare infrastructure and research capabilities. As precision medicine continues to evolve, the nucleic acid therapeutics market is poised for sustained expansion.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Therapy Type

• Antisense oligonucleotides (ASOs)
• Small interfering RNA (siRNA)
• Gene Therapies
• Aptamers
• Others (mRNA, etc.)

By Delivery Method

• Viral Vector-Based Delivery Systems
• Non-Viral Delivery Systems

By Route of Administration

• Intravenous
• Subcutaneous
• Others (Intrathecal, etc.)

By Therapeutic Area

• Neuromuscular Disorder
• Metabolic Disorders
• Cardiovascular Disorders
• Ophthalmological Disorders
• Oncological Disorders
• Others (Infectious diseases, Autoimmune, etc.)

By End-user

• Hospitals
• Academic And Research Institutes
• Others (Specialty Centers, Etc.)

COMPANIES PROFILED

• Novartis AG, Pfizer Inc., Sanofi, Novo Nordisk A/S, AstraZeneca plc, Alnylam Pharmaceuticals Inc., Amgen Inc, Sarepta Therapeutics Inc., Bluebird Bio Inc, CSL Behring LLC, Ferring Pharmaceuticals Inc., Krystal Biotech Inc., PTC Therapeutics Inc., Jazz Pharmaceuticals plc, Astellas Pharma Inc.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL NUCLEIC ACID THERAPEUTICS MARKET: BY THERAPY TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Therapy Type
• 4.2. Antisense oligonucleotides (ASOs) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Small interfering RNA (siRNA) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Gene Therapies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Aptamers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Others (mRNA, etc.) Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL NUCLEIC ACID THERAPEUTICS MARKET: BY DELIVERY METHOD 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Delivery Method
• 5.2. Viral Vector-Based Delivery Systems Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Non-Viral Delivery Systems Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL NUCLEIC ACID THERAPEUTICS MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Route Of Administration
• 6.2. Intravenous Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Subcutaneous Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Others (Intrathecal, etc.) Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL NUCLEIC ACID THERAPEUTICS MARKET: BY THERAPEUTIC AREA 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Therapeutic Area
• 7.2. Neuromuscular Disorder Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Metabolic Disorders Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Cardiovascular Disorders Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.5. Ophthalmological Disorders Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.6. Oncological Disorders Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.7. Others (Infectious diseases, Autoimmune, etc.) Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL NUCLEIC ACID THERAPEUTICS MARKET: BY END-USER 2022-2034 (USD MN)

• 8.1. Market Analysis, Insights and Forecast End-user
• 8.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.3. Academic And Research Institutes Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.4. Others (Specialty Centers, Etc.) Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 9. GLOBAL NUCLEIC ACID THERAPEUTICS MARKET: BY REGION 2022-2034 (USD MN)

• 9.1. Regional Outlook
• 9.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.2.1 By Therapy Type
  • 9.2.2 By Delivery Method
  • 9.2.3 By Route Of Administration
  • 9.2.4 By Therapeutic Area
  • 9.2.5 By End-user
  • 9.2.6 United States
  • 9.2.7 Canada
  • 9.2.8 Mexico
• 9.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.3.1 By Therapy Type
  • 9.3.2 By Delivery Method
  • 9.3.3 By Route Of Administration
  • 9.3.4 By Therapeutic Area
  • 9.3.5 By End-user
  • 9.3.6 United Kingdom
  • 9.3.7 France
  • 9.3.8 Germany
  • 9.3.9 Italy
  • 9.3.10 Russia
  • 9.3.11 Rest Of Europe
• 9.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.4.1 By Therapy Type
  • 9.4.2 By Delivery Method
  • 9.4.3 By Route Of Administration
  • 9.4.4 By Therapeutic Area
  • 9.4.5 By End-user
  • 9.4.6 India
  • 9.4.7 Japan
  • 9.4.8 South Korea
  • 9.4.9 Australia
  • 9.4.10 South East Asia
  • 9.4.11 Rest Of Asia Pacific
• 9.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.5.1 By Therapy Type
  • 9.5.2 By Delivery Method
  • 9.5.3 By Route Of Administration
  • 9.5.4 By Therapeutic Area
  • 9.5.5 By End-user
  • 9.5.6 Brazil
  • 9.5.7 Argentina
  • 9.5.8 Peru
  • 9.5.9 Chile
  • 9.5.10 Rest of Latin America
• 9.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.6.1 By Therapy Type
  • 9.6.2 By Delivery Method
  • 9.6.3 By Route Of Administration
  • 9.6.4 By Therapeutic Area
  • 9.6.5 By End-user
  • 9.6.6 Saudi Arabia
  • 9.6.7 UAE
  • 9.6.8 Israel
  • 9.6.9 South Africa
  • 9.6.10 Rest of the Middle East And Africa

Chapter 10. COMPETITIVE LANDSCAPE

• 10.1. Recent Developments
• 10.2. Company Categorization
• 10.3. Supply Chain & Channel Partners (based on availability)
• 10.4. Market Share & Positioning Analysis (based on availability)
• 10.5. Vendor Landscape (based on availability)
• 10.6. Strategy Mapping

Chapter 11. COMPANY PROFILES OF GLOBAL NUCLEIC ACID THERAPEUTICS INDUSTRY

• 11.1. Top Companies Market Share Analysis
• 11.2. Company Profiles
  • 11.2.1 Novartis AG
  • 11.2.2 Pfizer Inc
  • 11.2.3 Sanofi
  • 11.2.4 Novo Nordisk A/S
  • 11.2.5 AstraZeneca Plc
  • 11.2.6 Alnylam Pharmaceuticals Inc
  • 11.2.7 Amgen Inc
  • 11.2.8 Sarepta Therapeutics Inc
  • 11.2.9 Bluebird Bio Inc
  • 11.2.10 CSL Behring LLC
  • 11.2.11 Ferring Pharmaceuticals Inc
  • 11.2.12 Krystal Biotech Inc
  • 11.2.13 PTC Therapeutics Inc
  • 11.2.14 Jazz Pharmaceuticals Plc
  • 11.2.15 Astellas Pharma Inc